Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Amortization of Deferred Charges (2016 - 2025)

Historic Amortization of Deferred Charges for Ptc Therapeutics (PTCT) over the last 13 years, with Q3 2025 value amounting to $305000.0.

  • Ptc Therapeutics' Amortization of Deferred Charges rose 166.67% to $305000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year increase of 193.28%. This contributed to the annual value of $1.2 million for FY2024, which is 3603.84% down from last year.
  • Ptc Therapeutics' Amortization of Deferred Charges amounted to $305000.0 in Q3 2025, which was up 166.67% from $302000.0 recorded in Q2 2025.
  • In the past 5 years, Ptc Therapeutics' Amortization of Deferred Charges registered a high of $585000.0 during Q4 2022, and its lowest value of $295000.0 during Q2 2024.
  • In the last 5 years, Ptc Therapeutics' Amortization of Deferred Charges had a median value of $438000.0 in 2023 and averaged $406631.6.
  • Per our database at Business Quant, Ptc Therapeutics' Amortization of Deferred Charges crashed by 9204.39% in 2021 and then surged by 5039.37% in 2023.
  • Quarter analysis of 5 years shows Ptc Therapeutics' Amortization of Deferred Charges stood at $471000.0 in 2021, then grew by 24.2% to $585000.0 in 2022, then plummeted by 48.89% to $299000.0 in 2023, then increased by 2.68% to $307000.0 in 2024, then fell by 0.65% to $305000.0 in 2025.
  • Its last three reported values are $305000.0 in Q3 2025, $302000.0 for Q2 2025, and $299000.0 during Q1 2025.